

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/533,146
				Filing Date	April 27, 2005
				First Named Inventor	Belanoff, Joseph K.
				Art Unit	1617
Examiner Name					
Sheet	1	of	2	Attorney Docket Number	019904-003210US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	A1	US-5,250,529 A	10-05-1993	Theoharides,	
	A2	US-5,468,741 A	11-21-1995	Yen	
	A3	US-5,521,166 A	05-28-1996	Grubb	
	A4	US-6,380,223 A	04-30-2002	Dow et al.	
	A5	US-6,579,898 A	06-17-2003	Humphrey	
	A6	US-6,589,947 A	07-08-2003	Hamanaka et al.	
	A7	US-2003/0148987	08-07-2003	Morris et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	A8	WO	98/03179	A	01-29-1998	Mauskop, Alexander		<input type="checkbox"/>
								<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A9	ADELMAN, J., et al., "Current options for the prevention and treatment of migraine," <u>Clinical Therapeutics</u> , Vol. 23(6): 772-788 (June 2001)	<input type="checkbox"/>
	A10	AGARWAL, M.K., "The antilucocorticoid action of mifepristone," <u>Pharmacology and Therapeutics</u> , Vol. 70(3): 183-213 (1996)	<input type="checkbox"/>
	A11	HARDMAN, et al., "The Pharmaceutical Basis of Therapeutics," pp. 1430-1431 (1996)	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/533,146
				Filing Date	April 27, 2005
				First Named Inventor	Belanoff, Joseph K.
				Art Unit	1617
Examiner Name					
Sheet	2	of	2	Attorney Docket Number	019904-003210US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A12	KETTEL, et al., "Endocrine responses to long-term administration of the antiprogesterone RU-486 in patients with pelvic endometriosis," <u>Fertility and Sterility</u> , Database Biosis on ACS, Vol. 56(3): 402-407, Abstract (1991)	<input type="checkbox"/>
	A13	MORGAN, et al., "Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists," <u>J. Med. Chem.</u> , Vol. 45(12): 2417-2424 (June 2002)	<input type="checkbox"/>
	A14	SICUTERI, F., et al., "Naloxone effectiveness on spontaneous and induced perspective disorders in migraine," <u>Headache</u> , Vol. 23(4): 179-183 (1983)	<input type="checkbox"/>
	A15	The Merck Manual, fifteenth edition, 1987, pp. 1355-1356.	<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.